Capital at risk
Responsible Global Equity Income
Long-term dividend compounding is the eighth wonder of the world.
We focus on companies that can compound earnings and dividends effectively over long periods. These are rare but can deliver attractive returns.
Investing for a lifetime of income
Whether you require an income for years to come or are simply looking for attractive long-term capital appreciation, dividend growth investing could be what you’re looking for.
Responsible Global Equity Income Stewardship Report
Find out about our conversations with portfolio companies, shareholder vote activity and consideration of environmental, social and governance matters.
Responsible and dependable growth
We aim to deliver a dependable income and real growth in capital over the longterm by investing in responsible companies.
We believe the best way to do this is to invest in firms which can pay dependable dividends across the cycle, with the prospect of real profit growth, which will in turn lead to growth in dividends and capital.
These are rare and highly attractive to clients seeking income today and well into the future.
What do we mean by responsible? Beyond the exclusion of sin sectors, we mean investing in companies that are trying to address environmental, social and governance (ESG) issues and future-proofing their business.
A carefully selected portfolio
Our portfolio is a collection of carefully selected dividend-paying companies with attractive growth prospects.
Their sustainable earnings growth have the potential to support real growth in dividends, and they typically have resilient business models
Our strategy is managed with a growth mindset and a lengthy time horizon, focusing on dividend growth, not short-term yield.
Long-term dividend compounders are the unsung heroes of the market
Meet the managers
Documents
Philosophy and process
Explore our investment philosophy and the processes around how the team constructs the portfolio.
Stewardship report
Find out about our conversations with portfolio companies, shareholder vote activity and consideration of environmental, social and governance matters.
Explore further
Curious to learn more about our products and what we can offer you? Please get in touch.
Strategy portfolio holdings
A list of the top 10 holdings that the representative portfolio invests in.
All figures up to: 30 November 2024
| # | Holding | % of portfolio |
|---|---|---|
| 1 | Microsoft | 4.9% |
| 2 | Fastenal | 4.8% |
| 3 | TSMC | 4.2% |
| 4 | Watsco | 4.1% |
| 5 | Novo Nordisk | 3.9% |
| 6 | Procter & Gamble | 3.9% |
| 7 | Apple | 3.8% |
| 8 | Schneider Electric | 3.1% |
| 9 | Partners | 3.0% |
| 10 | CAR Group | 3.0% |
Please note
The information contained on this page is intended as a guide only and should not be relied upon when making investment decisions. All holdings information is unaudited. Source Baillie Gifford & Co. Please note that totals may not add due to rounding.
Explore further
Curious to learn more about our products and what we can offer you? Please get in touch.
Insights
Key articles, videos and podcasts relating to the strategy:
Filters
Insights
Global Income Growth Q3 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.
Eric Beinhocker: evolutionary economist
How successful companies harness the power of adaptation.
Global Income Growth Q2 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.
Global Income Growth Q1 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.
Novo Nordisk: tipping the scales
Charting how a century of innovation led to a game-changing weight-loss treatment.
Five years of Responsible Global Equity Income
Investment specialists reflect on the first five years of the Responsible Global Equity Income Strategy.
How dividend growth signals compounding
Investor James Dow explains why dividend growth indicates a company can compound its earnings.
A new recipe for weight loss
The huge growth potential of Novo Nordisk’s anti-obesity medicines.
Albemarle: salt flats and social responsibility
Why the lithium giant Albemarle engages in research and data monitoring.
Global Income Growth Q4 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.
Why growth, why now?
Tough times play to the partnership’s strengths: analysing what enables us to adapt and thrive amid rapid change.
Global Income Growth Q3 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.
TSMC’s decarbonisation dilemmas
TSMC’s progress in securing greener energy supplies in Taiwan.
Responsible Global Equity Income strategy update
Portfolio managers James Dow and Ross Mathison discuss current views and portfolio positioning against the backdrop of rising interest rates and market volatility.
Global Income Growth Q2 update
The Global Income Growth team reflects on recent performance, portfolio changes, and market developments.
Global Income Growth Q3 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.
Global Income Growth Q3 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.Eric Beinhocker: evolutionary economist
How successful companies harness the power of adaptation.Global Income Growth Q2 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.Global Income Growth Q1 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.Novo Nordisk: tipping the scales
Charting how a century of innovation led to a game-changing weight-loss treatment.Five years of Responsible Global Equity Income
Investment specialists reflect on the first five years of the Responsible Global Equity Income Strategy.How dividend growth signals compounding
Investor James Dow explains why dividend growth indicates a company can compound its earnings.A new recipe for weight loss
The huge growth potential of Novo Nordisk’s anti-obesity medicines.Albemarle: salt flats and social responsibility
Why the lithium giant Albemarle engages in research and data monitoring.Global Income Growth Q4 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.Why growth, why now?
Tough times play to the partnership’s strengths: analysing what enables us to adapt and thrive amid rapid change.Global Income Growth Q3 update
The Global Income Growth Team reflects on recent performance, portfolio changes and market developments.TSMC’s decarbonisation dilemmas
TSMC’s progress in securing greener energy supplies in Taiwan.Responsible Global Equity Income strategy update
Portfolio managers James Dow and Ross Mathison discuss current views and portfolio positioning against the backdrop of rising interest rates and market volatility.Global Income Growth Q2 update
The Global Income Growth team reflects on recent performance, portfolio changes, and market developments.
Explore further
Curious to learn more about our products and what we can offer you? Please get in touch.
Important information
The information provided does not constitute an offer of or solicitation for purchase or sale of securities or provision of any investment services. Baillie Gifford does not currently have any funds that offer securities under a simplified prospectus for general offer or sale within Canada. No securities regulatory authority in Canada has reviewed or in any way passed upon this website or the merits of any investment available, and any representation to the contrary is an offence.
Persons resident or domiciled in Canada should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to trade.
You can read details of our Legal and Important Information here.
Trade Matching Statement
This Trade-Matching Statement is being provided in accordance with National Instrument 24-101 -"Institutional Trade Matching and Settlement" and Companion Policy 24-101 CP (the "National
Instrument"). It applies to all trades that are subject to the National Instrument. View the whole statement.